Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis

Voriconazole is the drug of choice for invasive aspergillosis (IA) and drug levels are influenced by interactions with other drugs and genetic predisposition. We performed a retrospective analysis of voriconazole drug levels and investigated the adequacy of drug levels in pediatric cancer patients and hematopoietic cell transplant (HCT) recipients with IA.

[1]  P. Soler-Palacín,et al.  Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study. , 2012, The Journal of antimicrobial chemotherapy.

[2]  G. Thompson,et al.  Update on the optimal use of voriconazole for invasive fungal infections , 2011, Infection and drug resistance.

[3]  F. Farowski,et al.  Therapeutic Drug Monitoring of Voriconazole and Posaconazole , 2011, Pharmacotherapy.

[4]  H. Jafri,et al.  Pharmacokinetics, Safety, and Tolerability of Voriconazole in Immunocompromised Children , 2010, Antimicrobial Agents and Chemotherapy.

[5]  D. Marriott,et al.  Voriconazole concentrations and outcome of invasive fungal infections. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[6]  H. Shimada,et al.  Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age , 2010, Pediatric blood & cancer.

[7]  M. Xavier,et al.  Voriconazole therapeutic drug monitoring: focus on safety , 2010, Expert opinion on drug safety.

[8]  R. Jelliffe,et al.  Voriconazole pharmacokinetics and pharmacodynamics in children. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  M. Cuenca‐Estrella,et al.  Increasing Incidence of Invasive Aspergillosis in Pediatric Hematology Oncology Patients Over the Last Decade: A Retrospective Single Centre Study , 2009, Journal of pediatric hematology/oncology.

[10]  R. Danner,et al.  Accelerated Metabolism of Voriconazole and Its Partial Reversal by Cimetidine , 2009, Antimicrobial Agents and Chemotherapy.

[11]  Mats O. Karlsson,et al.  Population Pharmacokinetic Analysis of Voriconazole Plasma Concentration Data from Pediatric Studies , 2008, Antimicrobial Agents and Chemotherapy.

[12]  Janet L. Hoffman,et al.  Clinical Application of Voriconazole Concentrations in the Treatment of Invasive Aspergillosis , 2008, The Annals of pharmacotherapy.

[13]  J. Perfect,et al.  Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  J. Donnelly,et al.  Therapeutic Drug Monitoring of Voriconazole , 2008, Therapeutic drug monitoring.

[15]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  W. Steinbach,et al.  Pediatric Invasive Aspergillosis: A Multicenter Retrospective Analysis of 139 Contemporary Cases , 2008, Pediatrics.

[17]  D. Andes,et al.  Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. , 2008, Therapeutic drug monitoring.

[18]  Y. Bertrand,et al.  Invasive aspergillosis in a paediatric haematology department: a 15‐year review , 2008, Mycoses.

[19]  D. Denning,et al.  Voriconazole plasma monitoring , 2008, Archives of Disease in Childhood.

[20]  Raoul Herbrecht,et al.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  Thierry Buclin,et al.  Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  D. Andes,et al.  Voriconazole Therapeutic Drug Monitoring , 2006, Antimicrobial Agents and Chemotherapy.

[23]  M. Karlsson,et al.  Pharmacokinetics and Safety of Intravenous Voriconazole in Children after Single- or Multiple-Dose Administration , 2004, Antimicrobial Agents and Chemotherapy.

[24]  N. Wood,et al.  The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[25]  Richard Sylvester,et al.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.

[26]  N. Wood,et al.  Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens , 2002, Antimicrobial Agents and Chemotherapy.